Aro, Ionis collaboration to develop cell-specific delivery of ASOs

Ionis Pharmaceuticals, the RNA-targeted therapeutics specialist, will use Aro Biotherapeutics’ Centyrin technology to develop targeted cell- and tissue-specific delivery of antisense oligonucleotides (ASOs).

The companies will collaborate to create unique ASO-Centyrin conjugates that are designed to achieve tissue specific, therapeutically effective gene knockdown in extra-hepatic tissues with systemic administration.

Aro will be responsible for Centyrin discovery and will collaborate with Ionis to create lead ASO-Centyrin drug conjugates for further development.

Ionis, on the other hand, will be responsible for development and will have global commercialisation rights for each ASO-Centyrin drug conjugate. The parties will also collaborate on additional discovery programs.

Aro will receive an upfront cash payment, funding to support R&D efforts, and payments associated with the achievement of specific development and commercial milestones, up to $1.4 billion. In addition, Aro will receive royalties on net sales.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Valneva forges COVID-19 vaccine partnership with UK Gov

Valneva, a French vaccine company focused on prevention against diseases with major unmet needs, has forged a major vaccine partnership with the UK government...

Gilead Sciences to acquire Immunomedics for $21bn

Gilead Sciences is bolstering its oncology offering acquiring Immunomedics in a deal that values the latter at $21 billion. The agreement will provide Gilead with...

Study results support Owlstone Medical’s development of breath-based diagnostic tests for liver disease

Owlstone Medical, a leader in Breath Biopsy® for applications in early disease detection and precision medicine, has revealed the results of a patient study...

New partnership to take potential treatment for motor neurone disease into clinical trials

Researchers from the University of Sheffield’s Institute for Translational Neuroscience (SITraN) have been awarded a $700,000 drug development grant to progress a potential targeted...

Merck takes $1bn stake in Seattle Genetics as part of oncology collaboration

Merck is acquiring a $1 billion stake in Seattle Genetics has part of two new strategic oncology collaborations between the two companies. The companies will...

Related news

Takeda opens R&D cell therapy manufacturing facility

Takeda is expanding its cell therapy manufacturing capabilities with the opening of a new 24,000 sq ft cell therapy manufacturing facility at its R&D...

Valneva forges COVID-19 vaccine partnership with UK Gov

Valneva, a French vaccine company focused on prevention against diseases with major unmet needs, has forged a major vaccine partnership with the UK government...

Gilead Sciences to acquire Immunomedics for $21bn

Gilead Sciences is bolstering its oncology offering acquiring Immunomedics in a deal that values the latter at $21 billion. The agreement will provide Gilead with...

Study results support Owlstone Medical’s development of breath-based diagnostic tests for liver disease

Owlstone Medical, a leader in Breath Biopsy® for applications in early disease detection and precision medicine, has revealed the results of a patient study...